Top results

Antagonism/Agonism of Neurotransmitters & Associated Effects

Antagonism/Agonism of Neurotransmitters & Associated Effects

Test Your Knowledge on the antagonism and agonism of neurotransmitters and their associated effects in pharmacology.

Recommended on NP Psych Navigator

NP Spotlight: Moushumi Mukerji, MSN, PMHNP-BC, CNM, RN

NP Spotlights

NP Spotlight: Moushumi Mukerji, MSN, PMHNP-BC, CNM, RN

A career as a psychiatric nurse practitioner can be replete with challenges and opportunities. The NP Psych Navigator Spotlight is your chance to learn more about nurse practitioners who are working to advance the profession and mental health in general. In this installment of this series, we profile Moushumi Mukerji, MSN, PMHNP-BC, CNM, RN.
Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-term Outcomes of a Single-blind Randomized Study

Clinical Article

Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-term Outcomes of a Single-blind Randomized Study

Major depressive disorder (MDD) is a chronic and disabling condition that affects up to 12% of men and 25% of women. MDD is recurrent, with many patients not achieving complete recovery between depressive episodes. The aim of treatment for MDD is remission, which is associated with improved functioning and prognosis.
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder (MDD) Unresponsive to Antidepressant Treatment: the VAST-D Randomized Clinical Trial 

Clinical Article

Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder (MDD) Unresponsive to Antidepressant Treatment: the VAST-D Randomized Clinical Trial 

Major depressive disorder (MDD) is a chronic condition that affects millions of Americans. Unfortunately, first-line monotherapy does not adequately address depressive symptoms for some MDD patients. The VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) trial set out to determine the relative effectiveness and safety of 3 next-step treatments for MDD in patients who failed to respond adequately to at least 1 antidepressant treatment trial of adequate dose and duration. This clinical article summary shares the key findings of this landmark trial.
Providing Considerate Mental Health Care to Patients Who Are Black, Indigenous, and People of Color (BIPOC)

Clinical Insights

Providing Considerate Mental Health Care to Patients Who Are Black, Indigenous, and People of Color (BIPOC)

In this podcast, Moushumi Mukerji, MSN, PMHNP-BC, CNM, RN shares important considerations for providing mental health care to BIPOC patients.

Welcome To NP Psych Navigator

This website is intended for healthcare professionals inside the United States.
Please confirm that you are a healthcare professional inside the US.

No, I am not US Healthcare professional

You are now leaving NP Psych Navigator

Links to sites outside of NP Psych Navigator are provided as a resource to the viewer. AbbVie Inc accepts no responsibility for the content of non-AbbVie linked sites.

Redirect to:

Please to bookmark content